- Home
- ELVN vs MDXG Comparison
ELVN vs MDXG Comparison
Compare ELVN & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELVN | MDXG |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ELVN | MDXG |
|---|---|---|
| Price | $16.82 | $7.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $41.20 | $12.00 |
| AVG Volume (30 Days) | 661.3K | ★ 774.9K |
| Earning Date | 11-12-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $393,442,000.00 |
| Revenue This Year | N/A | $19.13 |
| Revenue Next Year | N/A | $2.11 |
| P/E Ratio | ★ N/A | $26.73 |
| Revenue Growth | N/A | ★ 14.77 |
| 52 Week Low | $13.30 | $5.79 |
| 52 Week High | $25.37 | $9.71 |
Technical Indicators
Market Signals| Indicator | ELVN | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 33.61 | 56.44 |
| Support Level | $17.31 | $6.62 |
| Resistance Level | $20.47 | $7.06 |
| Average True Range (ATR) | 1.39 | 0.23 |
| MACD | -0.41 | 0.05 |
| Stochastic Oscillator | 6.66 | 91.11 |
Price Performance
Historical ComparisonAbout ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.